Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Myriad Genetics Lost 28.4% in November

By Maxx Chatsko - Dec 10, 2018 at 9:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The genetic testing pioneer announced fiscal first-quarter 2019 results, but had to reduce full-year revenue guidance.

What happened

Shares of Myriad Genetics (MYGN 2.00%) fell over 28% last month, according to data provided by S&P Global Market Intelligence. The genetic testing pioneer announced mixed fiscal first-quarter 2019 operating results. On top of that, the business had to lower full-year revenue guidance after discovering "two issues that impacted revenue" for two of its growth products. Although the revision amounted to only 3% of the initial sales expectation, it wasn't the start to the fiscal year investors had been hoping for. 

So what

After years of struggling to offset falling sales of its lead products in hereditary cancer testing, Myriad Genetics believes recent diversification efforts will position its portfolio to return to growth in fiscal 2019. There were flashes of a recovery in the first quarter of the year, but the results were mixed.

An angry fist pounding a table as a falling stock chart is displayed on a tablet.

Image source: Getty Images.

While revenue jumped 13% compared to the year-ago period, and the business achieved a gross profit margin of 75.4%, that growth didn't come cheap. Sky-high operating expenses ate up nearly all gross profit and left behind an operating margin of just 0.6%. That means the business made $152.6 million in gross profit and just $1.2 million in operating profit.

After accounting for taxes and other expenses, Myriad Genetics lost a penny per share. It expects full-year 2019 earnings per share of just $0.40 to $0.45, unchanged from the original guidance.

Now what

The current performance puts investors in a tough spot. Myriad Genetics turned in twice as much revenue as its next closest competitor in the most recent quarter, but it's growing more slowly and is nowhere near as profitable. The business will need to lower operating expenses to boost earnings in fiscal 2020 and beyond. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Myriad Genetics, Inc. Stock Quote
Myriad Genetics, Inc.
MYGN
$21.97 (2.00%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.